290 related articles for article (PubMed ID: 18434637)
1. Selection of response criteria for clinical trials of sarcoma treatment.
Schuetze SM; Baker LH; Benjamin RS; Canetta R
Oncologist; 2008; 13 Suppl 2():32-40. PubMed ID: 18434637
[TBL] [Abstract][Full Text] [Related]
2. SARC-CTOS imaging symposium: introduction to the problem from a clinical perspective.
Benjamin RS
Oncologist; 2008; 13 Suppl 2():1-3. PubMed ID: 18434630
[TBL] [Abstract][Full Text] [Related]
3. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Lencioni R; Llovet JM
Semin Liver Dis; 2010 Feb; 30(1):52-60. PubMed ID: 20175033
[TBL] [Abstract][Full Text] [Related]
4. Response assessment in clinical trials: implications for sarcoma clinical trial design.
Jaffe CC
Oncologist; 2008; 13 Suppl 2():14-8. PubMed ID: 18434633
[TBL] [Abstract][Full Text] [Related]
5. Other endpoints in screening studies for soft tissue sarcomas.
Verweij J
Oncologist; 2008; 13 Suppl 2():27-31. PubMed ID: 18434636
[TBL] [Abstract][Full Text] [Related]
6. A statistical simulation study finds discordance between WHO criteria and RECIST guideline.
Mazumdar M; Smith A; Schwartz LH
J Clin Epidemiol; 2004 Apr; 57(4):358-65. PubMed ID: 15135836
[TBL] [Abstract][Full Text] [Related]
7. New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma.
Schmitt T; Kasper B
Expert Rev Anticancer Ther; 2009 Aug; 9(8):1159-67. PubMed ID: 19671035
[TBL] [Abstract][Full Text] [Related]
8. We should desist using RECIST, at least in GIST.
Benjamin RS; Choi H; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Charnsangavej C
J Clin Oncol; 2007 May; 25(13):1760-4. PubMed ID: 17470866
[TBL] [Abstract][Full Text] [Related]
9. RECIST revisited: a review of validation studies on tumour assessment.
Therasse P; Eisenhauer EA; Verweij J
Eur J Cancer; 2006 May; 42(8):1031-9. PubMed ID: 16616487
[TBL] [Abstract][Full Text] [Related]
10. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation.
Roedl JB; Colen RR; Holalkere NS; Fischman AJ; Choi NC; Blake MA
Radiother Oncol; 2008 Dec; 89(3):278-86. PubMed ID: 18701180
[TBL] [Abstract][Full Text] [Related]
11. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
12. Tumor response evaluation in oncology: current update.
Shanbhogue AK; Karnad AB; Prasad SR
J Comput Assist Tomogr; 2010 Jul; 34(4):479-84. PubMed ID: 20657213
[TBL] [Abstract][Full Text] [Related]
13. Assessing tumor response to therapy.
Weber WA
J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
[TBL] [Abstract][Full Text] [Related]
14. High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.
Stacchiotti S; Collini P; Messina A; Morosi C; Barisella M; Bertulli R; Piovesan C; Dileo P; Torri V; Gronchi A; Casali PG
Radiology; 2009 May; 251(2):447-56. PubMed ID: 19261927
[TBL] [Abstract][Full Text] [Related]
15. The management of adult soft tissue sarcomas.
Mendenhall WM; Indelicato DJ; Scarborough MT; Zlotecki RA; Gibbs CP; Mendenhall NP; Mendenhall CM; Enneking WF
Am J Clin Oncol; 2009 Aug; 32(4):436-42. PubMed ID: 19657238
[TBL] [Abstract][Full Text] [Related]
16. [Measurement of tumour response to cancer treatment: morphologic imaging role].
Ollivier L; Leclère J; Thiesse P; Di Stefano D; Vincent C
Bull Cancer; 2007 Feb; 94(2):171-7. PubMed ID: 17337386
[TBL] [Abstract][Full Text] [Related]
17. Fluorine-18-deoxyglucose-positron emission tomography imaging with magnetic resonance and computed tomographic correlation in the evaluation of bone and soft-tissue sarcomas: a pictorial essay.
Tewfik JN; Greene GS
Curr Probl Diagn Radiol; 2008; 37(4):178-88. PubMed ID: 18502325
[TBL] [Abstract][Full Text] [Related]
18. Radiologic measurements of tumor response to treatment: practical approaches and limitations.
Suzuki C; Jacobsson H; Hatschek T; Torkzad MR; Bodén K; Eriksson-Alm Y; Berg E; Fujii H; Kubo A; Blomqvist L
Radiographics; 2008; 28(2):329-44. PubMed ID: 18349443
[TBL] [Abstract][Full Text] [Related]
19. [New guidelines to evaluate the response to treatment "RECIST"].
Sasaki T
Gan To Kagaku Ryoho; 2000 Dec; 27(14):2179-84. PubMed ID: 11142160
[TBL] [Abstract][Full Text] [Related]
20. Endpoints for assessing drug activity in clinical trials.
Pazdur R
Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
